文献速递胸部肿瘤

局限期小细胞肺癌预防性颅脑照射:CONVERT试验二次分析

Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial.
PubMed 文献 · J Thorac Oncol · 2018-10-04

该分析基于CONVERT随机III期试验中接受预防性颅脑照射(PCI)的局限期小细胞肺癌患者数据,比较每日两次与每日一次胸部放疗后脑转移风险。结果显示两组PCI后脑转移发生率无差异,较大胸部肿瘤体积与更高脑转移风险相关,且仅肿瘤体积与总生存相关。

要点

  • 每日两次与每日一次胸部放疗后PCI患者的脑转移风险相同。
  • 较大的胸部肿瘤体积与更高的脑转移风险相关。
  • 胸部肿瘤体积是总生存的独立预后因素,PCI时机与总生存无关。

核心结论

  • 接受每日一次或每日两次胸部放疗的局限期小细胞肺癌患者,PCI后脑转移风险相同。

研究设计与样本

  • 基于CONVERT随机III期试验的二次分析,纳入547例患者中接受PCI的449例(82%)。

主要发现

  • PCI后75例(17%)发生脑转移,其中每日一次组35例(8%),每日两次组40例(9%)。
  • 单因素分析中,肿瘤体积与脑转移风险增加相关(p=0.007),与其他影像学进展事件风险增加相关(p=0.006)。
  • 多因素分析中,胸部肿瘤体积和ECOG体能状态评分与任一进展类型相关。
  • 接受PCI患者的中位总生存为29个月。
  • 单因素分析中,PCI时机(自化疗结束)、体重下降超过10%和胸部肿瘤体积是与总生存相关的预后因素;多因素分析中仅胸部肿瘤体积与总生存相关。

临床怎么用

  • 对于局限期小细胞肺癌患者,胸部放疗分割方式不影响PCI后脑转移风险。
  • 胸部肿瘤体积较大的患者脑转移风险更高,应加强监测。

局限性

  • 基线脑影像以CT为主(79%),可能影响脑转移检出敏感性。
  • 为二次分析,部分分析为单因素或多因素探索性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The impact of the dose and fractionation of thoracic radiotherapy on the risk of developing brain metastasis (BM) has not been evaluated prospectively in limited stage SCLC patients receiving prophylactic cerebral irradiation (PCI). METHODS: Data from patients treated with PCI from the CONVERT trial were analyzed. RESULTS: Four hundred forty-nine of 547 patients (82%) received PCI after completion of chemoradiotherapy. Baseline brain imaging consisted of computed tomographic scans in 356 of 449 patients (79%) and magnetic resonance imaging in 83 of 449 (18%) patients. PCI was delivered to 220 of 273 participants (81%) in the twice-daily (BD) group and 229 of 270 in the once-daily (OD) group (85%; p = 0.49). Total median PCI dose was 25 Gy in both the BD and OD groups (p = 0.74). In patients who received PCI, 75 (17%) developed BM (35 [8%] in OD and 40 [9%] in BD) and 173 (39%) other extracranial progression. In the univariate analysis, gross tumor volume (GTV) was associated with an increased risk of BM (p = 0.007) or other radiological progression events (p = 0.006), whereas in a multivariate analysis both thoracic GTV (tGTV) and ECOG performance score were associated with either progression type. The median overall survival (OS) of patients treated with PCI was 29 months. In the univariate analysis of OS, PCI timing from end of chemotherapy, weight loss of more than 10%, and tGTV were prognostic factors associated with OS. In the multivariate analysis, only tGTV was associated with OS. Delay between end of chemotherapy and PCI was not associated with OS. CONCLUSIONS: Patients receiving OD or BD thoracic radiotherapy have the same risk of developing BM. Larger tumors are associated with a higher risk of BM.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Levy A, Le Péchoux C, Mistry H, et al. Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. J Thorac Oncol. 2018. PMID: 30292850. doi:10.1016/j.jtho.2018.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。